BARI 2D STUDY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The BARI 2D trial is an NIH-sponsored, investigator-initiated, multicenter clinical trial whose objective is to determine, in patients with Type 2 diabetes mellitus and stable, documented coronary artery disease, whether 5-year mortality is lower with (1) a strategy of initial coronary revascularization (either PTCA or CABG) combined with intensive medical therapy vs intensive medical therapy alone, and (2) glycemic control achieved by an insulin sensitizaton regimen vs an insulin provision regimen (both to a target HbA1c level of <7.0%). UAB is one of about 50 clinical centers participating in this trial, of about 2,400 patients with follow-up of 5-7 years. The study is presently in its recruitment phase, and no results or publications have yet been forthcoming.